Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

ClinicalTrials.gov ID: NCT00529529

Public ClinicalTrials.gov record NCT00529529. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 26-week Treatment, Randomized, Multicenter, Double-blind, Double-dummy, Parallel-group Study to Assess the Safety of Indacaterol (300 and 600 µg o.d.) in Patients With Moderate to Severe Persistent Asthma, Using Salmeterol (50 µg b.i.d.) as an Active Control

Study identification

NCT ID
NCT00529529
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
805 participants

Conditions and interventions

Conditions

Interventions

  • Indacaterol 300 μg Drug
  • Salmeterol 50 μg Drug
  • Placebo to indacaterol Drug
  • Placebo to salmeterol Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2007
Primary completion
Jul 31, 2008
Completion
Jul 31, 2008
Last update posted
Aug 28, 2011

2007 – 2008

United States locations

U.S. sites
56
U.S. states
20
U.S. cities
47
Facility City State ZIP Site status
Novartis Investigator Site Glendale Arizona 85306
Novartis Investigator Site Phoenix Arizona 85306
Novartis Investigator Site Encinitas California 92024
Novartis Investigator Site Huntington Beach California 92647
Novartis Investigator Site Long Beach California 90806
Novartis Investigator Site Long Beach California 90808
Novartis Investigator Site Los Angeles California 90025
Novartis Investigator Site x 2 sites Oakland California 94609
Novartis Investigator Site Orange California 92868
Novartis Investigator Site Palmdale California 93551
Novartis Investigator Site San Diego California 92120
Novartis Investigator Site San Diego California 92123
Novartis Investigator Site Walnut Creek California 94598
Novartis Investigator Site Denver Colorado 80206
Novartis Investigator Site Denver Colorado 80230
Novartis Investigator Site Englewood Colorado 80112
Novartis Investigator Site Lakewood Colorado 80401
Novartis Investigator Site Brandon Florida 33511
Novartis Investigator Site Largo Florida 33770
Novartis Investigator Site Miami Florida 33143
Novartis Investigator Site Panama City Florida 32405
Novartis Investigator Site Pensacola Florida 32503
Novartis Investigator Site x 2 sites Pensacola Florida 32514
Novartis Investigator Site Tamarac Florida 33321
Novartis Investigator Site Albany Georgia 31707
Novartis Investigator Site Stockbridge Georgia 30281
Novartis Investigator Site Overland Park Kansas 66210
Novartis Investigator Site Overland Park Kansas 66215
Novartis Investigator Site Topeka Kansas 66606
Novartis Investigator Site Florence Kentucky 41017
Novartis Investigator Site Baltimore Maryland 21236
Novartis Investigator Site Wheaton Maryland 20902
Novartis Investigator Site North Dartmouth Massachusetts 02747
Novartis Investigator Site Ann Arbor Michigan 48106
Novartis Investigator Site Ypsilanti Michigan 48197
Novartis Investigator Site Springfield Missouri 65807
Novartis Investigator Site St Louis Missouri 63141
Novartis Investigator Site Omaha Nebraska 68130
Novartis Investigator Site Omaha Nebraska 68131
Novartis Investigator Site Northfield New Jersey 08225
Novartis Investigator Site Rockville Centre New York 11570
Novartis Investigator Site Charlotte North Carolina 28207
Novartis Investigator Site High Point North Carolina 27262
Novartis Investigator Site Winston-Salem North Carolina 27103
Novartis Investigator Site Cincinnati Ohio 45252
Novartis Investigator Site Toledo Ohio 43617
Novartis Investigator Site Edmond Oklahoma 73003
Novartis Investigator Site Oklahoma City Oklahoma 73120
Novartis Investigator Site Greenville South Carolina 29615
Novartis Investigator Site Dallas Texas 75231
Novartis Investigator site Houston Texas 77024
Novartis Investigator Site Houston Texas 77030
Novartis Investigator Site Houston Texas 77054
Novartis Investigator Site Houston Texas 77070
Novartis Investigator Site Kirkland Washington 98034
Novartis Investigator Site Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 70 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00529529, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 28, 2011 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00529529 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →